Continue reading below for the latest news and updates from Senomyx SNMX partners Pepsico and Nestle related to the research, development, and commercialization agreements in place for sweet and savory flavor ingredients for food and beverage products.
Pepsi transcript quotes courtesy of Morningstar. Note that Pepsi Next does not contain any Senomyx flavor ingredients. There was, as usual, no direct discussion of the SNMX collaboration.
"In North American beverages, Pepsi NEXT is off to a strong start and we've just launched two new limited-time-only favors, Pepsi NEXT Cherry Vanilla and Pepsi NEXT Paradise Mango to satisfy the thirst of cola lovers looking for unique fruit flavor blends, both with 60% less sugar than regular colas."
"We have Pepsi NEXT in the marketplace that is delivering about what we expected. Very happy with it and in the just recent few weeks we've just launched a new TV campaign and also two new flavors of the products. So, let's say cautiously optimistic on that brand."
We all know that it has been a rough month or two for the biotech sector, fueled by the overall market decline following the debt ceiling debate as well as the biotech sector weakness following $DNDN Dendreon's weak Provenge prostate cancer vaccine sales and resulting 70% drop in stock value. This has resulted in a large list of biotech companies trading at extremely low valuations. While I can't promise that prices won't continue lower, I think now is the time for careful research and evaluation on stocks you may want to own in the coming months. I feel some of the companies listed below are worth owning at today's prices (8/23/11), others may decline even further. For full disclosure, click here for a current list of which stocks I own among those I cover. As always, complete your own research and consider your circumstances before taking any action based on my thoughts.
Keep reading below the jump for my stock by stock analysis: